抗血管生成药物联合化疗在复发性卵巢癌治疗中的研究进展OACSTPCD
Research Progress of the Combination of Antiangiogenic Agents and Chemotherapy for Recurrent Ovarian Cancer
卵巢癌是妇科常见的恶性肿瘤之一,其发生、发展及肿瘤细胞的浸润转移离不开新生血管,因此通过抑制肿瘤新生血管形成,是治疗卵巢癌的有效途径之一.目前主要研究的抗血管生成药物包括血管内皮生长因子抑制剂(如贝伐单抗)、酪氨酸激酶抑制剂(如索拉菲尼、帕唑帕尼、西地尼布等)和血管生成素抑制剂(如Trebananib).大量的Ⅱ、Ⅲ期临床试验表明抗血管靶向药物联合化疗为复发性铂敏感性或铂耐药性卵巢癌的治疗带来了曙光,明显延长了疾病无进展生存期.综述不同抗血管靶向…查看全部>>
Ovarian cancer is one of the common gynecologic malignant tumors. The development of it and the metastases of tumor cells need new blood vessels. Therefore, by inhibiting tumor angiogenesis is one of effective ways to treat ovarian cancer. The main antiangiogenic agents included vascular endothelial growth factor inhibitor (such as Bevacizumab), tyrosine kinase inhibitors (such as Sorafenib, Pazopanib and Cediranib), and angiogenin inhibitor (such as Trebana…查看全部>>
张洁
730000 兰州,兰州大学第一临床医学院
卵巢肿瘤抗肿瘤联合化疗方案抗血管生成药物贝伐单抗西地尼布复发性卵巢癌
Ovarian neoplasmsAntineoplastic combined chemotherapy protocolsAntiangiogenic agentsBevacizumabCediranibRecurrence ovarian cancer
《国际妇产科学杂志》 2016 (1)
70-74,5
评论